vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Bristow Group Inc. (VTOL). Click either name above to swap in a different company.
Bristow Group Inc. is the larger business by last-quarter revenue ($377.3M vs $196.9M, roughly 1.9× Pacira BioSciences, Inc.). On growth, Bristow Group Inc. posted the faster year-over-year revenue change (6.7% vs 5.1%). Bristow Group Inc. produced more free cash flow last quarter ($47.8M vs $43.5M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs 5.8%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Bristow Helicopters Limited is a British civil helicopter operator originally based at Aberdeen Airport, Scotland, which is currently a part of the U.S.-based Bristow Group which in turn has its corporate headquarters in Houston, Texas, U.S. In 2020, Bristow Group was merged with Era Helicopters, a large U.S.-based commercial helicopter operator that was previously a division of Era Aviation, with the two companies then continuing to use the Bristow name.
PCRX vs VTOL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.9M | $377.3M |
| Net Profit | — | $18.4M |
| Gross Margin | 79.5% | — |
| Operating Margin | 1.2% | 8.5% |
| Net Margin | — | 4.9% |
| Revenue YoY | 5.1% | 6.7% |
| Net Profit YoY | — | -42.1% |
| EPS (diluted) | $0.05 | $0.61 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.9M | $377.3M | ||
| Q3 25 | $179.5M | $386.3M | ||
| Q2 25 | $181.1M | $376.4M | ||
| Q1 25 | $168.9M | $350.5M | ||
| Q4 24 | $187.3M | $353.5M | ||
| Q3 24 | $168.6M | $365.1M | ||
| Q2 24 | $178.0M | $359.7M | ||
| Q1 24 | $167.1M | $337.1M |
| Q4 25 | — | $18.4M | ||
| Q3 25 | $5.4M | $51.5M | ||
| Q2 25 | $-4.8M | $31.7M | ||
| Q1 25 | $4.8M | $27.4M | ||
| Q4 24 | — | $31.8M | ||
| Q3 24 | $-143.5M | $28.2M | ||
| Q2 24 | $18.9M | $28.2M | ||
| Q1 24 | $9.0M | $6.6M |
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — | ||
| Q1 24 | 71.6% | — |
| Q4 25 | 1.2% | 8.5% | ||
| Q3 25 | 3.5% | 13.1% | ||
| Q2 25 | 4.7% | 11.3% | ||
| Q1 25 | 1.2% | 9.6% | ||
| Q4 24 | 13.2% | 9.0% | ||
| Q3 24 | -82.8% | 9.1% | ||
| Q2 24 | 15.9% | 12.4% | ||
| Q1 24 | 7.9% | 6.8% |
| Q4 25 | — | 4.9% | ||
| Q3 25 | 3.0% | 13.3% | ||
| Q2 25 | -2.7% | 8.4% | ||
| Q1 25 | 2.8% | 7.8% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | -85.1% | 7.7% | ||
| Q2 24 | 10.6% | 7.8% | ||
| Q1 24 | 5.4% | 2.0% |
| Q4 25 | $0.05 | $0.61 | ||
| Q3 25 | $0.12 | $1.72 | ||
| Q2 25 | $-0.11 | $1.07 | ||
| Q1 25 | $0.10 | $0.92 | ||
| Q4 24 | $0.38 | $1.07 | ||
| Q3 24 | $-3.11 | $0.95 | ||
| Q2 24 | $0.39 | $0.96 | ||
| Q1 24 | $0.19 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $238.4M | $286.2M |
| Total DebtLower is stronger | $372.2M | $671.5M |
| Stockholders' EquityBook value | $693.1M | $1.1B |
| Total Assets | $1.3B | $2.3B |
| Debt / EquityLower = less leverage | 0.54× | 0.63× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $238.4M | $286.2M | ||
| Q3 25 | $246.3M | $245.5M | ||
| Q2 25 | $445.9M | $251.8M | ||
| Q1 25 | $493.6M | $191.1M | ||
| Q4 24 | $484.6M | $247.5M | ||
| Q3 24 | $453.8M | $200.3M | ||
| Q2 24 | $404.2M | $178.6M | ||
| Q1 24 | $325.9M | $140.6M |
| Q4 25 | $372.2M | $671.5M | ||
| Q3 25 | $376.7M | $675.0M | ||
| Q2 25 | $580.5M | $705.2M | ||
| Q1 25 | $583.4M | $701.9M | ||
| Q4 24 | $585.3M | $689.8M | ||
| Q3 24 | — | $629.1M | ||
| Q2 24 | — | $594.2M | ||
| Q1 24 | — | $544.1M |
| Q4 25 | $693.1M | $1.1B | ||
| Q3 25 | $727.2M | $1.0B | ||
| Q2 25 | $757.8M | $984.4M | ||
| Q1 25 | $798.5M | $931.7M | ||
| Q4 24 | $778.3M | $891.7M | ||
| Q3 24 | $749.6M | $899.2M | ||
| Q2 24 | $879.3M | $849.1M | ||
| Q1 24 | $892.2M | $820.7M |
| Q4 25 | $1.3B | $2.3B | ||
| Q3 25 | $1.3B | $2.3B | ||
| Q2 25 | $1.5B | $2.3B | ||
| Q1 25 | $1.6B | $2.2B | ||
| Q4 24 | $1.6B | $2.1B | ||
| Q3 24 | $1.5B | $2.1B | ||
| Q2 24 | $1.6B | $2.0B | ||
| Q1 24 | $1.6B | $1.9B |
| Q4 25 | 0.54× | 0.63× | ||
| Q3 25 | 0.52× | 0.65× | ||
| Q2 25 | 0.77× | 0.72× | ||
| Q1 25 | 0.73× | 0.75× | ||
| Q4 24 | 0.75× | 0.77× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.66× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.7M | $76.9M |
| Free Cash FlowOCF − Capex | $43.5M | $47.8M |
| FCF MarginFCF / Revenue | 22.1% | 12.7% |
| Capex IntensityCapex / Revenue | 0.1% | 7.7% |
| Cash ConversionOCF / Net Profit | — | 4.17× |
| TTM Free Cash FlowTrailing 4 quarters | $136.7M | $56.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $43.7M | $76.9M | ||
| Q3 25 | $60.8M | $23.1M | ||
| Q2 25 | $12.0M | $99.0M | ||
| Q1 25 | $35.5M | $-603.0K | ||
| Q4 24 | $33.1M | $51.1M | ||
| Q3 24 | $53.9M | $66.0M | ||
| Q2 24 | $53.2M | $33.7M | ||
| Q1 24 | $49.1M | $26.7M |
| Q4 25 | $43.5M | $47.8M | ||
| Q3 25 | $57.0M | $-6.2M | ||
| Q2 25 | $9.3M | $67.4M | ||
| Q1 25 | $26.9M | $-52.7M | ||
| Q4 24 | $31.0M | $-32.4M | ||
| Q3 24 | $49.8M | $9.0M | ||
| Q2 24 | $51.6M | $-16.7M | ||
| Q1 24 | $46.3M | $-37.9M |
| Q4 25 | 22.1% | 12.7% | ||
| Q3 25 | 31.7% | -1.6% | ||
| Q2 25 | 5.1% | 17.9% | ||
| Q1 25 | 15.9% | -15.0% | ||
| Q4 24 | 16.6% | -9.2% | ||
| Q3 24 | 29.6% | 2.5% | ||
| Q2 24 | 29.0% | -4.6% | ||
| Q1 24 | 27.7% | -11.2% |
| Q4 25 | 0.1% | 7.7% | ||
| Q3 25 | 2.2% | 7.6% | ||
| Q2 25 | 1.5% | 8.4% | ||
| Q1 25 | 5.1% | 14.9% | ||
| Q4 24 | 1.1% | 23.6% | ||
| Q3 24 | 2.4% | 15.6% | ||
| Q2 24 | 0.9% | 14.0% | ||
| Q1 24 | 1.7% | 19.2% |
| Q4 25 | — | 4.17× | ||
| Q3 25 | 11.20× | 0.45× | ||
| Q2 25 | — | 3.12× | ||
| Q1 25 | 7.37× | -0.02× | ||
| Q4 24 | — | 1.61× | ||
| Q3 24 | — | 2.34× | ||
| Q2 24 | 2.82× | 1.20× | ||
| Q1 24 | 5.47× | 4.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
VTOL
| Offshore Energy Services | $247.5M | 66% |
| Government Services | $100.1M | 27% |
| Other | $21.9M | 6% |
| Related Party | $7.8M | 2% |
